Compare LITS & FTW.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LITS | FTW.WS |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 29.6M |
| IPO Year | 2003 | N/A |
| Metric | LITS | FTW.WS |
|---|---|---|
| Price | $0.86 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 256.5K | N/A |
| Earning Date | 11-10-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.81 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | N/A |
| 52 Week High | $2.00 | N/A |
| Indicator | LITS | FTW.WS |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | N/A |
| Support Level | $0.74 | N/A |
| Resistance Level | $1.08 | N/A |
| Average True Range (ATR) | 0.10 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 15.74 | 0.00 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.